Summary
Boston Scientific Corporation (BSX) announced on March 3, 2021, a significant strategic acquisition: the definitive agreement to purchase Lumenis LTD.'s global Surgical business unit. This acquisition, for an upfront cash payment of $1.07 billion, will expand BSX's portfolio with innovative laser systems and fibers primarily for urology and otolaryngology procedures. The transaction is expected to close in the second half of 2021, subject to customary closing conditions. Lumenis will retain its Aesthetics and Ophthalmology business units, which will be separated into a new entity prior to the acquisition's completion. This move signals BSX's intent to strengthen its position in key surgical specialties and drive future growth through targeted inorganic expansion.
Key Highlights
- 1Boston Scientific to acquire Lumenis' global Surgical business unit for $1.07 billion in cash.
- 2Acquisition focuses on energy-based medical solutions, specifically laser systems and fibers for urology and otolaryngology.
- 3Transaction is expected to close in the second half of 2021, subject to customary conditions.
- 4Lumenis' Aesthetics and Ophthalmology businesses will be separated before the acquisition closes.
- 5This is a strategic move to enhance Boston Scientific's surgical portfolio and market presence.
- 6The filing includes a press release detailing the acquisition and a cautionary statement regarding forward-looking information.